Judith J. Li, is a Partner at Lilly Asia Ventures (LAV), based in Menlo Park and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith joined LAV in 2013 and has held board appointments at a variety of LAV’s portfolio companies, including Inhibrx (INBX: acquired by Sanofi), Structure (GPCR), TMunity (acquired by Gilead) and Just Biotherapeutics (acquired by Evotec). Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. In addition to her role at LAV, Judith has held various advisory board and non-profit board positions. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School.